MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

Search

Harmony Biosciences Holdings Inc

Chiusa

SettoreSettore sanitario

26.35 -0.42

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

25.91

Massimo

26.39

Metriche Chiave

By Trading Economics

Entrata

-5.8M

40M

Vendite

16M

200M

P/E

Media del settore

8.577

37.257

EPS

0.92

Margine di Profitto

19.839

Dipendenti

268

EBITDA

3M

59M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+70.8% upside

Dividendi

By Dow Jones

Utili prossimi

28 ott 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-511M

1.5B

Apertura precedente

26.77

Chiusura precedente

26.35

Notizie sul Sentiment di mercato

By Acuity

50%

50%

172 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Harmony Biosciences Holdings Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 ott 2025, 21:45 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million -- Update

13 ott 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million

13 ott 2025, 17:03 UTC

I principali Market Mover

Canaan ADRs Climb on Launch of Gas-to-Computing Pilot in Canada

13 ott 2025, 23:53 UTC

Discorsi di Mercato

Gold Rises, Buoyed by Bullish Fundamental Backdrop -- Market Talk

13 ott 2025, 23:39 UTC

Discorsi di Mercato

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

13 ott 2025, 22:15 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

13 ott 2025, 22:15 UTC

Discorsi di Mercato

Precinct Properties NZ's Equity Raising Looks Opportunistic -- Market Talk

13 ott 2025, 21:57 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 ott 2025, 21:36 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

13 ott 2025, 21:36 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

13 ott 2025, 21:36 UTC

Discorsi di Mercato

Fletcher's Near-Term Headwinds Don't Cloud Earnings Opportunity -- Market Talk

13 ott 2025, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965M -- Update

13 ott 2025, 21:06 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 ott 2025, 20:52 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Sachs to Acquire Industry Ventures for Up to $965M

13 ott 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

13 ott 2025, 20:35 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Expects to Close Deal in 1Q

13 ott 2025, 20:34 UTC

Acquisizioni, Fusioni, Takeovers

Industry Ventures Will Be Part of Goldman's External Manager Platform, External Investing Group

13 ott 2025, 20:33 UTC

Acquisizioni, Fusioni, Takeovers

Industry Ventures Currently Manages $7B of Assets Under Supervision

13 ott 2025, 20:32 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Sachs: Deal to Include Up to $300M of Additional Contingent Consideration Based on Future Performance Through 2030

13 ott 2025, 20:31 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Sachs: Consideration to Include $665M Cash and Equity Payable at Closing

13 ott 2025, 20:29 UTC

Acquisizioni, Fusioni, Takeovers

Goldman Sachs to Buy VC Firm Industry Ventures

13 ott 2025, 19:05 UTC

Discorsi di Mercato

Oil Futures Pick Up on Easing U.S.-China Tension -- Market Talk

13 ott 2025, 18:59 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

13 ott 2025, 18:26 UTC

Discorsi di Mercato

Precious Metals Close at New Record Highs -- Market Talk

13 ott 2025, 18:10 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

13 ott 2025, 18:10 UTC

Discorsi di Mercato

Broadcom's OpenAI Deal Highlights AI Opportunity -- Market Talk

13 ott 2025, 17:05 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

13 ott 2025, 17:05 UTC

Discorsi di Mercato

OpenAI Deal Offers Huge Upside to Broadcom's Earnings -- Market Talk

13 ott 2025, 16:03 UTC

Acquisizioni, Fusioni, Takeovers

Umicore Completes Sale, Subsequent Lease-in of Permanent Gold Inventories

13 ott 2025, 15:35 UTC

Discorsi di Mercato

Precious Metals Push Record Highs Further -- Market Talk

Confronto tra pari

Modifica del prezzo

Harmony Biosciences Holdings Inc Previsione

Obiettivo di Prezzo

By TipRanks

70.8% in crescita

Previsioni per 12 mesi

Media 45.33 USD  70.8%

Alto 62 USD

Basso 31 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Harmony Biosciences Holdings Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

10 ratings

9

Acquista

0

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

29.8 / N/ASupporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Very Strong Bearish Evidence

Sentiment

By Acuity

172 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat